Bridge Therapeutics
About Bridge Therapeutics
Bridge Therapeutics®, based in Birmingham, Ala., is an innovative development-stage specialty pharmaceutical company pursuing U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals of a patented (U.S. Patent #8410092) drug combination, BT-205, for the treatment of chronic pain in opioid-experienced patients. The investigational drug BT-205 is a unique combination of two synergistic chronic pain drugs—the partial-agonist opioid buprenorphine and the NSAID meloxicam—delivered in a state-of-the-art sublingual formulation. The dosing and delivery method will be a commercial advantage over the current alternatives. Bridge Therapeutics' goal is to make the BT-205 compound and other investigational new drug candidates available to millions of patients in which addictive and potentially dangerous full-agonist opioids such as oxycodone and morphine are ineffective and/or unsatisfactory.
YEAR FOUNDED:
2016
LEADERSHIP:
CEO: Dr. Greg Sullivan
4 articles with Bridge Therapeutics
-
Global biopharmaceutical companies are pooling their respective resources against difficult-to-treat tumors, CNS diseases and idiopathic pulmonary fibrosis.
-
Bridge Therapeutics Announces It Will Seek FDA Approval for BT-219, a Treatment for Opioid Dependence in the Coming Months
11/7/2019
Bridge Therapeutics Inc. announced that it has received feedback from the Food and Drug Administration from a Pre-Investigational New Drug meeting for the development of BT-219, a therapy to treat Opioid Dependence.
-
Bridge Therapeutics Announces the Addition of Edward J. Minskoff to Its Board of Directors
4/23/2019
Bridge Therapeutics, an innovative startup pharmaceutical company developing a practical and safe therapy for chronic pain, is pleased to announce the addition of Edward J. Minskoff to its board of directors.
-
Bridge Therapeutics To Present At BioTrinity 2017 Conference In London
5/11/2017